MBX Biosciences elects Tiba Aynechi and Kent Hawryluk as Class I directors; Carl Gordon departs board

MBX Biosciences, Inc.

Stockholders elected Tiba Aynechi (24.3M for) and P. Kent Hawryluk (24.4M for) to three-year terms ending 2028.
Carl L. Gordon, Ph.D., CFA departed the board effective June 5, 2025; his term ended at the annual meeting.
Ratification of Ernst & Young as independent auditor for FY2025 passed with 27.8M for, 3,467 against.
Annual meeting held June 5, 2025; 33.4M shares outstanding as of April 11 record date.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Carl L. Gordon

Director

MBX · MBX Biosciences, Inc.

Effective: 2025-06-05
Filed: June 6, 2025, 7:59 PM ET

Also effective as of June 5, 2025 was the departure of Carl L. Gordon, Ph.D., CFA from the Company's board of directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carl L. Gordon departed as Director at MBX Biosciences, Inc..

Action: departed
Role: Director

Exact text from the filing

Also effective as of June 5, 2025 was the departure of Carl L. Gordon, Ph.D., CFA from the Company's board of directors.

View on SEC.gov

MBX Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-082697

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.